Link is here: https://www.nature.com/naturecareers/job/postdoctoral-scholar-biochemistry-and-molecular-biology-medical-university-of-south-carolina-musc-761242
Dr. Sahin has recently accepted a Professor and SmartState Endowed Chair position at the Dept. of Biochemistry & Molecular Biology and Hollings Cancer Center at Medical University of South Carolina. Starting May 1, our lab is located at HO703 at Read More …
This 5-year grant will address the mechanisms of resistance to chemotherapy in highly aggressive breast cancers using cutting-edge methodologies, including testing our recently developed LOX inhibitors. NEW positions are available for highly motivated postdocs and graduate students.
This work aims to enhance the efficacy of antibody-drug conjugate (ADC) therapy in aggressive breast cancer. Here is the press release: https://marykayashfoundation.org/what-we-do/cancer-research/grant-recipients/
If you are interested in working at the intersection of mechanisms of drug resistance, metastasis and drug discovery, please apply via: https://www.nature.com/naturecareers/job/postdoctoral-fellow-in-cancer-research-university-of-south-carolina-columbia-sc-746191
Our R01 grant aiming at blocking tumor growth and metastasis in highly aggressive breast cancers has been funded. In this exciting project, we will target highly aggressive breast cancers with our newly developed inhibitor.
Details of the position and how to apply are here.
This study introduces endogenous ADA2 expression as a prognostic factor and PEGADA2 as a novel immunotherapy for cancer. Read the article here.
Dr. Sahin co-organized a Mini Symposium with Dr. Taru Muranen (Dana-Farber Cancer Institute) and Rebeca San Martin (University of Tennessee, Knoxville) which was hosted by Joe Cotter from the American Cancer Society – February 17, 2021. The Mini Symposium was Read More …
Dr. Sahin presented our recent work on how we take genome/transcriptome-wide approaches to identify regulators of drug resistance, identify mechanisms of resistance and develop novel drug candidates on Feb 12, 2021 at the Seminar Series of Izmir Biomedicine and Genome Read More …